tyrosine kinase inhibitors for non-small cell lung cancer and eye metastasis; disease relapse or a new entity?
نویسندگان
چکیده
lung cancer is still diagnosed in advanced stage and most patients do not have the opportunity for surgical treatment. although in the recent years new diagnostic equipment is available such as the radial and linear endobronchial ultrasound (ebus) and electromagnetic fiberoptic bronchoscopy. however; novel targeted therapies with tyrosine kinase inhibitors of second generation and immunotherapy are available. in this commentary we will focus on eye metastasis after initiation of tyrosine kinase inhibitors due to epidermal growth factor mutation of lung cancer adenocarcinoma.
منابع مشابه
Tyrosine Kinase Inhibitors for Non-Small Cell Lung Cancer and Eye Metastasis: Disease Relapse or a New Entity?
Lung cancer is still diagnosed during the advanced stage of the disease and most patients do not have the opportunity for surgical treatment, despite the new diagnostic equipment that has been made available in recent years, such as the radial and linear endobronchial ultrasound (EBUS) and electromagnetic fiberoptic bronchoscopy. However, novel targeted therapies with second generation tyrosine...
متن کاملTyrosine kinase inhibitors: new molecules in non-small cell lung cancer (EGFR AND ALK)
Lung cancer is a tumor pathology that includes a group of neoplasms with different biological characteristics, which determine the course of the disease and the potential treatment response depending on the subtype diagnosed. Non-small lung carcinoma corresponds to 85 % of all lung cancers. Adenocarcinoma is the most common histologic subtype of this group. In the United States approximately 13...
متن کاملSelection of Non-small Cell Lung Cancer Patients for Intercalated Chemotherapy and Tyrosine Kinase Inhibitors
BACKGROUND When treating patients with advanced non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors and chemotherapy, intercalated schedule with time separation between the two classes of drugs should avoid their mutual antagonism. In a survey of published trials, we focus on relation between eligibility criteria and effectiveness of intercalated treatment. METHODS Published do...
متن کاملSmall molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer.
Despite recent developments in the diagnosis and conventional treatment of non small cell lung cancer (NSCLC), the prognosis remains unsatisfactory, with 5-year survival rates of approximately 15% for all stages. To date, chemotherapy represents the standard treatment for advanced-non small lung cancer, but efficacy of currently available cytotoxic drugs is modest. Median survival does not exce...
متن کاملDrug resistance to EGFR tyrosine kinase inhibitors for non-small cell lung cancer.
Non-small cell lung cancer (NSCLC) harboring an activating mutation within the epidermal growth factor receptor (EGFR) was defined as a clinically distinct molecular group. These lesions show oncogene addiction to EGFR and dramatic responses to the EGFR tyrosine kinase inhibitors (TKIs). Several large Phase III trials have shown that EGFR-TKIs improved the progression-free survival of patients ...
متن کاملDrug Delivery and Drug Resistance: EGFR-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
The epidermal growth factor receptor (EGFR) pathway has emerged as an important target in the treatment of non-small cell lung cancer (NSCLC). Currently available EGFR inhibitors approved for the therapy of NSCLC include the small molecules erlotinib and gefitinib. They are administered orally and interfere with the intracellular tyrosine kinase domain. These agents appear most effective in pat...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
medical hypothesis, discovery and innovation ophthalmology journalجلد ۵، شماره ۴، صفحات ۰-۰
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023